Portfolio Holdings Detail for ISIN IE00BYXG2H39
| Stock Name / Fund | iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares IV Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300ZP07LMR36K1T02 |
| ETF Ticker | BTEC(USD) LSE |
| ETF Ticker | BTEK(GBP) LSE |
| ETF Ticker | 2B70(EUR) F |
| ETF Ticker | 2B70.DE(EUR) CXE |
| ETF Ticker | BTEC.LS(USD) CXE |
| ETF Ticker | BTEK.LS(GBP) CXE |
| ETF Ticker | BTEC.L(GBP) LSE |
| ETF Ticker | BTEK.L(GBP) LSE |
Holdings detail for ATXS
| Stock Name | Astria Therapeutics Inc |
| Ticker | ATXS(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US04635X1028 |
Show aggregate ATXS holdings
News associated with ATXS
- HC Wainwright Issues Positive Forecast for Astria Therapeutics (NASDAQ:ATXS) Stock Price
- Astria Therapeutics (NASDAQ:ATXS – Free Report) had its price target lifted by HC Wainwright from $16.00 to $20.00 in a research note issued to investors on Wednesday, MarketBeat reports. They currently have a buy rating on the biotechnology company’s stock. ATXS has been the subject of a number of other reports. JMP Securities increased their […] - 2025-09-18 05:10:30
- Astria Therapeutics (NASDAQ:ATXS) Receives “Overweight” Rating from Cantor Fitzgerald
- Cantor Fitzgerald reissued their overweight rating on shares of Astria Therapeutics (NASDAQ:ATXS – Free Report) in a report issued on Wednesday,Benzinga reports. They currently have a $49.00 price objective on the biotechnology company’s stock. Other analysts have also recently issued reports about the company. HC Wainwright reissued a “buy” rating and set a $16.00 price […] - 2025-09-18 04:26:49
- Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $29.00 Average PT from Analysts
- Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) has been assigned a consensus rating of “Buy” from the seven analysts that are covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price […] - 2025-08-29 03:04:48
- Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $29.00 Consensus Target Price from Analysts
- Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) have earned an average recommendation of “Buy” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 […] - 2025-08-04 02:26:49
- UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)
- UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS – Free Report) by 13.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 63,452 shares of the biotechnology company’s stock after acquiring an additional 7,756 shares during the quarter. UBS AM a […] - 2025-06-12 05:30:57
- Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Consensus Recommendation of “Buy” by Analysts
- Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) has earned a consensus rating of “Buy” from the eight research firms that are presently covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12 month price […] - 2025-06-12 05:30:53
- Janus Henderson Group PLC Purchases Shares of 17,700 Astria Therapeutics, Inc. (NASDAQ:ATXS)
- Janus Henderson Group PLC purchased a new position in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 17,700 shares of the biotechnology company’s stock, valued at approximately $159,000. Other institutional investors also recently bought and […] - 2025-05-26 04:44:52
- Cubist Systematic Strategies LLC Invests $137,000 in Astria Therapeutics, Inc. (NASDAQ:ATXS)
- Cubist Systematic Strategies LLC purchased a new position in Astria Therapeutics, Inc. (NASDAQ:ATXS – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 15,278 shares of the biotechnology company’s stock, valued at approximately $137,000. Other institutional investors […] - 2025-05-19 04:58:50
- Tower Research Capital LLC TRC Has $47,000 Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS)
- Tower Research Capital LLC TRC raised its position in Astria Therapeutics, Inc. (NASDAQ:ATXS – Free Report) by 109.2% in the fourth quarter, HoldingsChannel reports. The fund owned 5,299 shares of the biotechnology company’s stock after purchasing an additional 2,766 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Astria Therapeutics were worth $47,000 […] - 2025-05-13 04:22:49
- Barclays PLC Grows Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)
- Barclays PLC raised its stake in Astria Therapeutics, Inc. (NASDAQ:ATXS – Free Report) by 5.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 97,820 shares of the biotechnology company’s stock after acquiring an additional 5,169 shares during the quarter. Barclays PLC’s […] - 2025-05-06 04:40:47
- Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $26.60
- Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) has received an average recommendation of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective […] - 2025-04-01 02:08:51
- Intech Investment Management LLC Has $242,000 Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS)
- Intech Investment Management LLC boosted its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS – Free Report) by 31.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,104 shares of the biotechnology company’s stock after purchasing an additional 6,439 shares […] - 2025-03-27 06:28:51
- HC Wainwright Reiterates Buy Rating for Astria Therapeutics (NASDAQ:ATXS)
- Astria Therapeutics (NASDAQ:ATXS – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $16.00 price target on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 124.09% from the stock’s current […] - 2025-03-13 04:23:00
- Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Acquired by New York State Common Retirement Fund
- New York State Common Retirement Fund grew its position in Astria Therapeutics, Inc. (NASDAQ:ATXS – Free Report) by 67.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 10,720 shares of the biotechnology company’s stock after buying an additional 4,300 shares during the quarter. New York State Common Retirement Fund’s holdings in Astria Therapeutics were […] - 2025-03-06 08:19:23
- Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Consensus Recommendation of “Buy” by Brokerages
- Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) has received an average rating of “Buy” from the eight ratings firms that are currently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target […] - 2025-02-14 06:22:52
- Astria Therapeutics (NASDAQ:ATXS) Rating Increased to Strong-Buy at Citizens Jmp
- Citizens Jmp upgraded shares of Astria Therapeutics (NASDAQ:ATXS – Free Report) to a strong-buy rating in a report published on Friday,Zacks.com reports. Other equities analysts have also recently issued research reports about the company. Oppenheimer upped their target price on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a […] - 2025-02-03 04:16:51
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) ATXS holdings
| Date | Number of ATXS Shares Held | Base Market Value of ATXS Shares | Local Market Value of ATXS Shares | Change in ATXS Shares Held | Change in ATXS Base Value | Current Price per ATXS Share Held | Previous Price per ATXS Share Held |
|---|
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of ATXS by Blackrock for IE00BYXG2H39
Show aggregate share trades of ATXS| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-10-06 | BUY | 288 | 7.690 | 7.840 | 7.825 | USD 2,254 | 6.16 |
| 2025-10-03 | BUY | 672 | 7.520 | 7.895 | 7.857 | USD 5,280 | 6.15 |
| 2025-10-02 | BUY | 96 | 7.690 | 7.830 | 7.816 | USD 750 | 6.14 |
| 2025-09-30 | BUY | 192 | 7.280 | 7.405 | 7.393 | USD 1,419 | 6.13 |
| 2025-09-26 | BUY | 192 | 7.300 | 7.360 | 7.354 | USD 1,412 | 6.12 |
| 2025-09-25 | BUY | 192 | 7.150 | 7.295 | 7.281 | USD 1,398 | 6.11 |
| 2025-09-24 | SELL | -4,012 | 7.270 | 7.700 | 7.657 | USD -30,720 | 6.10  Loss of -6,230 on sale |
| 2025-09-18 | BUY | 109 | 7.480 | 7.790 | 7.759 | USD 846 | 6.10 |
| 2025-09-17 | BUY | 327 | 7.390 | 7.830 | 7.786 | USD 2,546 | 6.09 |
| 2025-09-11 | SELL | -108 | 7.840 | 7.860 | 7.858 | USD -849 | 6.06 Loss of -195 on sale |
| 2025-09-10 | BUY | 216 | 7.490 | 7.905 | 7.864 | USD 1,699 | 6.05 |
| 2025-09-05 | SELL | -108 | 7.520 | 7.570 | 7.565 | USD -817 | 6.02 Loss of -167 on sale |
| 2025-08-29 | SELL | -327 | 6.180 | 6.590 | 6.549 | USD -2,142 | 6.01 Loss of -176 on sale |
| 2025-08-27 | BUY | 216 | 6.510 | 6.804 | 6.775 | USD 1,463 | 6.01 |
| 2025-08-26 | SELL | -108 | 6.670 | 6.680 | 6.679 | USD -721 | 6.00 Loss of -73 on sale |
| 2025-08-25 | BUY | 108 | 6.420 | 6.810 | 6.771 | USD 731 | 6.00 |
| 2025-08-20 | SELL | -428 | 6.310 | 6.410 | 6.400 | USD -2,739 | 5.99 Loss of -174 on sale |
| 2025-08-18 | BUY | 214 | 6.780 | 6.998 | 6.976 | USD 1,493 | 5.99 |
| 2025-08-08 | SELL | -212 | 6.280 | 6.670 | 6.631 | USD -1,406 | 5.97 Loss of -141 on sale |
| 2025-08-05 | BUY | 106 | 7.020 | 7.205 | 7.186 | USD 762 | 5.95 |
| 2025-08-01 | SELL | -317 | 6.560 | 6.860 | 6.830 | USD -2,165 | 5.94 Loss of -283 on sale |
| 2025-07-30 | BUY | 424 | 6.730 | 7.340 | 7.279 | USD 3,086 | 5.92 |
| 2025-07-17 | SELL | -212 | 6.240 | 6.489 | 6.464 | USD -1,370 | 5.89 Loss of -122 on sale |
| 2025-07-11 | SELL | -856 | 6.370 | 6.795 | 6.753 | USD -5,780 | 5.87 Loss of -753 on sale |
| 2025-07-07 | BUY | 324 | 6.200 | 6.360 | 6.344 | USD 2,055 | 5.85 |
| 2025-07-02 | BUY | 5,940 | 5.730 | 5.908 | 5.890 | USD 34,988 | 5.85 |
| 2025-06-25 | BUY | 214 | 5.650 | 5.790 | 5.776 | USD 1,236 | 5.87 |
| 2025-06-20 | BUY | 4,643 | 5.860 | 6.130 | 6.103 | USD 28,336 | 5.87 |
| 2025-06-11 | BUY | 184 | 5.790 | 5.940 | 5.925 | USD 1,090 | 5.87 |
| 2025-06-10 | BUY | 184 | 5.710 | 5.940 | 5.917 | USD 1,089 | 5.88 |
| 2025-06-04 | SELL | -92 | 5.280 | 5.428 | 5.413 | USD -498 | 5.89  Profit of 44 on sale |
| 2025-04-23 | BUY | 92 | 5.200 | 5.305 | 5.294 | USD 487 | 6.42 |
| 2025-04-10 | SELL | -736 | 4.060 | 4.280 | 4.258 | USD -3,134 | 6.74 Profit of 1,824 on sale |
| 2025-04-08 | SELL | -92 | 3.750 | 4.760 | 4.659 | USD -429 | 6.82 Profit of 199 on sale |
| 2025-04-07 | SELL | -92 | 4.500 | 4.850 | 4.815 | USD -443 | 6.86 Profit of 188 on sale |
| 2025-04-04 | SELL | -460 | 4.655 | 5.070 | 5.029 | USD -2,313 | 6.90 Profit of 859 on sale |
| 2025-04-01 | BUY | 368 | 5.400 | 5.560 | 5.544 | USD 2,040 | 6.94 |
| 2025-03-31 | SELL | -276 | 5.340 | 5.700 | 5.664 | USD -1,563 | 6.97 Profit of 361 on sale |
| 2025-03-14 | SELL | -1,472 | 6.450 | 6.820 | 6.783 | USD -9,985 | 7.13 Profit of 513 on sale |
| 2025-03-07 | SELL | -184 | 6.190 | 6.460 | 6.433 | USD -1,184 | 7.21 Profit of 143 on sale |
| 2025-03-04 | SELL | -92 | 6.210 | 6.390 | 6.372 | USD -586 | 7.28 Profit of 84 on sale |
| 2025-02-25 | BUY | 184 | 6.390 | 6.560 | 6.543 | USD 1,204 | 7.42 |
| 2025-02-19 | SELL | -92 | 7.000 | 7.080 | 7.072 | USD -651 | 7.50 Profit of 39 on sale |
| 2025-02-13 | BUY | 276 | 7.020 | 7.050 | 7.047 | USD 1,945 | 7.57 |
| 2025-02-12 | BUY | 92 | 6.990 | 7.050 | 7.044 | USD 648 | 7.59 |
| 2025-02-11 | BUY | 368 | 6.840 | 7.000 | 6.984 | USD 2,570 | 7.62 |
| 2025-01-17 | BUY | 368 | 7.500 | 7.900 | 7.860 | USD 2,892 | 7.94 |
| 2025-01-16 | BUY | 368 | 7.750 | 7.954 | 7.934 | USD 2,920 | 7.96 |
| 2025-01-10 | SELL | -182 | 7.450 | 8.140 | 8.071 | USD -1,469 | 8.56 Profit of 88 on sale |
| 2025-01-08 | SELL | -368 | 8.350 | 8.580 | 8.557 | USD -3,149 | 8.97 Profit of 152 on sale |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of ATXS
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 29,149 | 0 | 101,264 | 28.8% |
| 2025-09-18 | 38,676 | 0 | 240,328 | 16.1% |
| 2025-09-17 | 56,517 | 0 | 208,578 | 27.1% |
| 2025-09-16 | 39,754 | 0 | 207,756 | 19.1% |
| 2025-09-15 | 45,588 | 0 | 228,230 | 20.0% |
| 2025-09-12 | 68,562 | 0 | 147,445 | 46.5% |
| 2025-09-11 | 45,065 | 0 | 168,372 | 26.8% |
| 2025-09-10 | 76,314 | 0 | 207,046 | 36.9% |
| 2025-09-09 | 96,729 | 0 | 185,256 | 52.2% |
| 2025-09-08 | 56,906 | 200 | 173,184 | 32.9% |
| 2025-09-05 | 49,851 | 0 | 275,829 | 18.1% |
| 2025-09-04 | 35,827 | 0 | 166,285 | 21.5% |
| 2025-09-03 | 47,231 | 0 | 109,730 | 43.0% |
| 2025-09-02 | 43,544 | 0 | 126,698 | 34.4% |
| 2025-08-29 | 28,091 | 0 | 70,559 | 39.8% |
| 2025-08-28 | 35,668 | 0 | 101,285 | 35.2% |
| 2025-08-27 | 20,417 | 0 | 51,095 | 40.0% |
| 2025-08-26 | 23,725 | 0 | 67,815 | 35.0% |
| 2025-08-25 | 51,505 | 0 | 102,672 | 50.2% |
| 2025-08-22 | 55,727 | 0 | 157,354 | 35.4% |
| 2025-08-21 | 27,587 | 0 | 114,763 | 24.0% |
| 2025-08-20 | 52,094 | 0 | 81,211 | 64.1% |
| 2025-08-19 | 29,714 | 0 | 68,485 | 43.4% |
| 2025-08-18 | 40,375 | 0 | 89,691 | 45.0% |
| 2025-08-15 | 35,323 | 0 | 167,191 | 21.1% |
| 2025-08-14 | 44,577 | 0 | 181,370 | 24.6% |
| 2025-08-13 | 40,476 | 0 | 111,224 | 36.4% |
| 2025-08-12 | 33,680 | 0 | 76,924 | 43.8% |
| 2025-08-11 | 46,154 | 0 | 122,038 | 37.8% |
| 2025-08-08 | 30,619 | 0 | 57,663 | 53.1% |
| 2025-08-07 | 35,813 | 0 | 89,122 | 40.2% |
| 2025-08-06 | 33,027 | 0 | 54,198 | 60.9% |
| 2025-08-05 | 22,678 | 0 | 77,363 | 29.3% |
| 2025-08-04 | 50,090 | 0 | 120,872 | 41.4% |
| 2025-08-01 | 37,022 | 0 | 56,358 | 65.7% |
| 2025-07-31 | 33,169 | 0 | 55,362 | 59.9% |
| 2025-07-30 | 53,689 | 0 | 109,472 | 49.0% |
| 2025-07-29 | 26,823 | 0 | 45,000 | 59.6% |
| 2025-07-28 | 25,106 | 0 | 38,260 | 65.6% |
| 2025-07-25 | 21,229 | 221 | 31,859 | 66.6% |
| 2025-07-24 | 18,812 | 0 | 29,930 | 62.9% |
| 2025-07-23 | 13,872 | 0 | 32,615 | 42.5% |
| 2025-07-22 | 29,561 | 0 | 48,846 | 60.5% |
| 2025-07-21 | 44,522 | 0 | 98,089 | 45.4% |
| 2025-07-18 | 26,980 | 0 | 48,525 | 55.6% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.
Copyright Market Footprint Ltd. Privacy Policy